877.777.1874 • www.asuragen.com *Research Use Only. Not for use in diagnostic procedures. Multiplex assay for 7 distinct mutations in KRAS codon 12 and 13 Co-detection of a KRAS endogenous control sequence in the same reaction Positive and Negative control samples provided independently No cross reactivity between mutations and automatic detection on the Luminex ® 100 IS TM or 200 TM systems Simultaneous detection and identification in a single reaction well of a 96-well plate Assess DNA quality and integrity in each DNA specimen Assess validity of the PCR, hybridization and detection steps in each run Easy to interpret qualitative results KRAS is an oncogene involved in the epidermal growth factor receptor (EGFR) signaling pathway that controls cancer cell proliferation and apoptosis. Recently, there has been increased interest in the use of specific biomarkers in colorectal cancer (CRC) and other cancers treated with EGFR targeted therapies. The Signature ® KRAS Mutations 7 (RUO)* assay is based on the Signature ® Technology Platform for the rapid multiplex analysis of nucleic acid sequences, allowing detection of up to 100 DNA or RNA targets in a single reaction well. The Signature ® KRAS Mutations (RUO)* provides comprehensive information on 7 distinct mutations within codons 12 and 13 of the KRAS oncogene. The 96-well assay format enables characterization of KRAS mutation status in approximately 4 hours using a broad input range of genomic DNA isolated from cultured cells or fresh, frozen or formalin-fixed paraffin-embedded (FFPE) specimens. The streamlined workflow and multiplex assay format increase specimen throughput, decrease reagents/supplies use and reaction set up time, and overall, reduce the cost per individual mutation tested. The same technology is also available for detection of 12 KRAS mutations and BRAF V600E as part of the Signature ® KRAS/BRAF Mutations (RUO)* Assay. Signature ® KRAS Mutations 7 (RUO)* Figure 1: Seven distinct KRAS mutations can be detected by the assay in a single reaction (right). The streamlined assay workflow is optimized for rapid time to results with minimum hands-on time (above). G12S (GGT>AGT) G12R (GGT>CGT) G12C (GGT>TGT) G12D (GGT>GAT) G12A (GGT>GCT G12V (GGT>GTT) G13D (GGC>GAC) Key Attributes of Signature ® KRAS Mutations 7 (RUO)*:
2
Embed
Signature KRAS Mutations 7 (RUO)* - Theradiag · 877.777.1874 • 2500-0220REV2 Excellent analytical specificity across all 7 mutations using the Signature® KRAS Mutations 7 Assay*
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.